Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT03383146
Registration number
NCT03383146
Ethics application status
Date submitted
19/12/2017
Date registered
26/12/2017
Date last updated
23/11/2021
Titles & IDs
Public title
A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis Study 04
Query!
Scientific title
A 52-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients With Diabetic Gastroparesis
Query!
Secondary ID [1]
0
0
2017-002144-33
Query!
Secondary ID [2]
0
0
RLM-MD-04
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Gastroparesis
0
0
Query!
Diabetes Mellitus
0
0
Query!
Condition category
Condition code
Oral and Gastrointestinal
0
0
0
0
Query!
Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon
Query!
Neurological
0
0
0
0
Query!
Other neurological disorders
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Placebo
Treatment: Drugs - Relamorelin
Placebo comparator: Placebo - Placebo injected subcutaneously twice daily for up to 52 weeks. De novo (New) participants, who did not participate in the previous relamorelin studies, began the study with a 2-week placebo run-in.
Experimental: Relamorelin 10 µg - Relamorelin 10 micrograms (µg) injected subcutaneously twice daily for up to 52 weeks. De novo (New) participants, who did not participate in the previous relamorelin studies, began the study with a 2-week placebo run-in.
Treatment: Drugs: Placebo
Placebo injected subcutaneously twice daily.
Treatment: Drugs: Relamorelin
Relamorelin 10 µg injected subcutaneously twice daily.
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Change From Baseline to Week 12 in the Weekly Diabetic Gastroparesis Symptom Severity Score (DGSSS)
Query!
Assessment method [1]
0
0
Participants assessed the severity of diabetic gastroparesis symptoms daily using the Diabetic Gastroparesis Symptom Severity Diary (DGSSD), recorded in an electronic diary (e-diary). The DGSSS was derived as the sum of the weekly averages of the 4 DGSSD items: nausea, abdominal pain, postprandial fullness and bloating. Each symptom was scored using an 11-point ordinal scale where: 0=no or not at all uncomfortable to 10=worst possible or most uncomfortable for a total possible DGSSS of 0 (best) to 40 (worst). A negative change from Baseline indicates improvement. Baseline was defined as the average of the 2 weekly DGSSS from the run-in period of the previous study or the run-in period of this study for new participants.
Query!
Timepoint [1]
0
0
Baseline (14-day Run-in Period of the previous relamorelin study RLM-MD-01 or RLM-MD-02 for rollover participants or Day -14 to Day -1 for new participants) to Week 12 of this study
Query!
Primary outcome [2]
0
0
Change From Baseline to Week 52 in the Weekly Average DGSSS
Query!
Assessment method [2]
0
0
Participants assessed the severity of diabetic gastroparesis symptoms daily using the DGSSD, recorded in an electronic diary (e-diary). The DGSSS was derived as the sum of the weekly averages of the 4 DGSSD items: nausea, abdominal pain, postprandial fullness and bloating. Each symptom was scored using an 11-point ordinal scale where: 0=no or not at all uncomfortable to 10=worst possible or most uncomfortable for a total possible DGSSS of 0 (best) to 40 (worst). The average weekly scores at Week 52 were the average of the DGSSS scores from Week 49 to Week 52. A negative change from Baseline indicates improvement. Baseline was defined as the average of the 2 weekly DGSSS from the run-in period of the previous study or the run-in period of this study for new participants.
Query!
Timepoint [2]
0
0
Baseline (14-day Run-in Period of the previous relamorelin study RLM-MD-01 or RLM-MD-02 for rollover participants or Day -14 to Day -1 for new participants) to Week 52 of this study
Query!
Primary outcome [3]
0
0
Number of Participants Who Experienced One or More Treatment-Emergent Adverse Events (TEAE)
Query!
Assessment method [3]
0
0
An adverse event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study treatment. A TEAE is an AE that begins or worsens after receiving study drug.
Query!
Timepoint [3]
0
0
First dose of study drug to within 30 days of the last dose of study drug (Up to approximately 56 weeks)
Query!
Primary outcome [4]
0
0
Number of Participants With Potential Clinically Significant (PCS) Clinical Laboratory Results
Query!
Assessment method [4]
0
0
Clinical Laboratory tests included Hematology, Chemistry and Urinalysis tests. The investigator determined if the results were clinically significant. Only those categories where at least 1 participant had a non-PCS value at Baseline and met the PCS criterion at least once during postbaseline are reported.
Query!
Timepoint [4]
0
0
Up to 52 weeks
Query!
Primary outcome [5]
0
0
Number of Participants With Clinically Meaningful Trends for Vital Signs
Query!
Assessment method [5]
0
0
Vital Signs included assessments of heart rate, respiratory rate, systolic and diastolic blood pressure, and body temperature. The investigator determined if the abnormal results were clinically significant.
Query!
Timepoint [5]
0
0
Up to 52 weeks
Query!
Primary outcome [6]
0
0
Number of Participants With Clinically Significant Abnormal Electrocardiogram (ECG) Results
Query!
Assessment method [6]
0
0
A standard 12-lead ECG was performed. The investigator determined if the abnormal results were clinically significant.
Query!
Timepoint [6]
0
0
Up to 52 weeks
Query!
Primary outcome [7]
0
0
Number of Participants With a =1% Increase in Glycosylated Hemoglobin A1c (HbA1c)
Query!
Assessment method [7]
0
0
Query!
Timepoint [7]
0
0
Up to 52 weeks
Query!
Primary outcome [8]
0
0
Number of Participants With Anti-relamorelin Antibody Testing Results by Visit
Query!
Assessment method [8]
0
0
A blood sample was collected that was sent to a laboratory for an anti-relamorelin antibody screening test. A positive screening test was confirmed by an immunodepletion assay. The number of participants in each of the following categories are reported: Negative Screening Test, Positive Screening Test, Negative Confirmatory Test, and Positive Confirmatory Test at each time point.
Query!
Timepoint [8]
0
0
Baseline (Day 1), Day 84, Day 364, and End of Treatment (Up to Day 364)
Query!
Eligibility
Key inclusion criteria
Two different groups of participants may enter into the study:
1. Rollover Participants
Participants who were not randomization-eligible at the end of the Run-in Period of lead-in studies RLM-MD-01 (NCT03285308) or RLM-MD-02 (NCT03426345) are eligible to be randomized in the study if all of the following criteria apply:
•In the lead-in studies, participants must have met all screening visit and Run-in Period criteria for randomization into the Treatment Period (including compliance with dosing, entry of diary data into the Diabetic Gastroparesis Symptom Severity Diary (DGSSD)) except that:
* They had zero vomiting episodes and an average daily Diabetic Gastroparesis Symptom Severity Score (DGSSS) of =12 at the end of the lead-in study Run-in Period, as reported using the electronic hand-held device; OR
* They had vomiting episodes and an average daily DGSSS of =12 but <16 at the end of the lead-in study Run-in Period, as reported using the electronic hand-held device
2. De Novo Participants
* Type 1 Diabetes Mellitus (T1DM) or Type 2 Diabetes Mellitus (T2DM) of at least 5 years' duration, with controlled and stable blood glucose levels and hemoglobin A1c (HBA1c) =11%
* DG defined as at least a 3-month history prior to Screening of symptoms (one of which must be nausea) on an ongoing basis that are suggestive of gastroparesis (GP) (e.g., nausea, abdominal pain, postprandial fullness, bloating, vomiting, and early satiety)
* Compliance with the entry of data into the hand-held electronic device during the Run-in Period
* Compliance with administration of subcutaneous (SC) twice daily injections during the Run-in Period
* The average of the daily DGSSS from the 2-week, Run-in Period must be =12
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
1. Both Rollover and De Novo Participants
•Participants with a known allergy or hypersensitivity to the study treatments and their excipients (i.e., mannitol or phenol)
2. Rollover Participants
•Participants will be excluded from this study if any of the lead-in study exclusion criteria apply at the Screening Visit and at the end of the Run-in Period for randomization into the Treatment Period of studies RLM-MD-01 and RLM-MD-02, except as specified in the inclusion criteria
3. De Novo Participants
* History of anorexia nervosa, binge-eating, bulimia, or other eating disorder within 5 years of the Screening Visit
* History of intestinal malabsorption or pancreatic exocrine insufficiency
* History of belching disorders, other nausea and vomiting disorders
* Gastric or duodenal ulcer within 3 months of Screening
* History of malignancy in the 3 years prior to Screening, except for adequately treated basal cell or squamous cell skin cancer, or in situ cervical cancer
* Currently receiving parenteral feeding or presence of a nasogastric or other enteral tube for feeding or decompression
* Use of metoclopramide, domperidone, prucalopride, macrolide antibiotics (e.g., erythromycin, clarithromycin, azithromycin), or other drugs considered to be GI promotility agents for at least 10 days prior to the start of the Run-in Period
* Currently taking opiates, or expecting to use opiates during the course of the clinical study
* Treatment with glucagon-like peptide-1 (GLP-1) agonist for at least 6 weeks prior to the start of the Run-in Period
* History of pyloric injection of botulinum toxin within 6 months of screening
* History of gastric surgery such as fundoplication, gastrectomy, gastric pacemaker placement, vagotomy, or bariatric procedure (a history of diagnostic endoscopy is not exclusionary)
* Randomization in any previous study in which relamorelin was a treatment
* Allergic to, or intolerant of egg, wheat, milk, or algae, as these are components of the gastric emptying breath test (GEBT) study meal
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Stopped early
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/02/2018
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
5/11/2020
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
450
Query!
Recruitment in Australia
Recruitment state(s)
NSW,SA,VIC
Query!
Recruitment hospital [1]
0
0
Nepean Hospital - Kingswood
Query!
Recruitment hospital [2]
0
0
Royal Adelaide Hospital - Central Adelaide Local Health Network Incorporated - Adelaide
Query!
Recruitment hospital [3]
0
0
Royal Melbourne Hospital - Parkville
Query!
Recruitment postcode(s) [1]
0
0
2747 - Kingswood
Query!
Recruitment postcode(s) [2]
0
0
5000 - Adelaide
Query!
Recruitment postcode(s) [3]
0
0
3050 - Parkville
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Alabama
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Arizona
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Arkansas
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
California
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Colorado
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Connecticut
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Florida
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Georgia
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Idaho
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Illinois
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Indiana
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Iowa
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Kansas
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Kentucky
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Louisiana
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
Maryland
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
Michigan
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
Minnesota
Query!
Country [19]
0
0
United States of America
Query!
State/province [19]
0
0
Missouri
Query!
Country [20]
0
0
United States of America
Query!
State/province [20]
0
0
Montana
Query!
Country [21]
0
0
United States of America
Query!
State/province [21]
0
0
Nebraska
Query!
Country [22]
0
0
United States of America
Query!
State/province [22]
0
0
Nevada
Query!
Country [23]
0
0
United States of America
Query!
State/province [23]
0
0
New Jersey
Query!
Country [24]
0
0
United States of America
Query!
State/province [24]
0
0
New Mexico
Query!
Country [25]
0
0
United States of America
Query!
State/province [25]
0
0
New York
Query!
Country [26]
0
0
United States of America
Query!
State/province [26]
0
0
North Carolina
Query!
Country [27]
0
0
United States of America
Query!
State/province [27]
0
0
Ohio
Query!
Country [28]
0
0
United States of America
Query!
State/province [28]
0
0
Oklahoma
Query!
Country [29]
0
0
United States of America
Query!
State/province [29]
0
0
Oregon
Query!
Country [30]
0
0
United States of America
Query!
State/province [30]
0
0
Pennsylvania
Query!
Country [31]
0
0
United States of America
Query!
State/province [31]
0
0
South Carolina
Query!
Country [32]
0
0
United States of America
Query!
State/province [32]
0
0
South Dakota
Query!
Country [33]
0
0
United States of America
Query!
State/province [33]
0
0
Tennessee
Query!
Country [34]
0
0
United States of America
Query!
State/province [34]
0
0
Texas
Query!
Country [35]
0
0
United States of America
Query!
State/province [35]
0
0
Utah
Query!
Country [36]
0
0
United States of America
Query!
State/province [36]
0
0
Virginia
Query!
Country [37]
0
0
United States of America
Query!
State/province [37]
0
0
Washington
Query!
Country [38]
0
0
United States of America
Query!
State/province [38]
0
0
West Virginia
Query!
Country [39]
0
0
Argentina
Query!
State/province [39]
0
0
Buenos Aires Province
Query!
Country [40]
0
0
Argentina
Query!
State/province [40]
0
0
Buenos Aires
Query!
Country [41]
0
0
Argentina
Query!
State/province [41]
0
0
Ciudad Autonoma deBuenos Aires
Query!
Country [42]
0
0
Argentina
Query!
State/province [42]
0
0
Santa Fe
Query!
Country [43]
0
0
Argentina
Query!
State/province [43]
0
0
Tucuman
Query!
Country [44]
0
0
Argentina
Query!
State/province [44]
0
0
Cordoba
Query!
Country [45]
0
0
Argentina
Query!
State/province [45]
0
0
Corrientes
Query!
Country [46]
0
0
Argentina
Query!
State/province [46]
0
0
Córdoba
Query!
Country [47]
0
0
Austria
Query!
State/province [47]
0
0
Steiermark
Query!
Country [48]
0
0
Austria
Query!
State/province [48]
0
0
Vorarlberg
Query!
Country [49]
0
0
Austria
Query!
State/province [49]
0
0
Salzburg
Query!
Country [50]
0
0
Austria
Query!
State/province [50]
0
0
Steyr
Query!
Country [51]
0
0
Belgium
Query!
State/province [51]
0
0
Antwerp
Query!
Country [52]
0
0
Belgium
Query!
State/province [52]
0
0
Brussel
Query!
Country [53]
0
0
Belgium
Query!
State/province [53]
0
0
West-Vlaanderen
Query!
Country [54]
0
0
Brazil
Query!
State/province [54]
0
0
CE
Query!
Country [55]
0
0
Brazil
Query!
State/province [55]
0
0
Distrito Federal
Query!
Country [56]
0
0
Brazil
Query!
State/province [56]
0
0
PA
Query!
Country [57]
0
0
Brazil
Query!
State/province [57]
0
0
Rio Grande Do Sul
Query!
Country [58]
0
0
Brazil
Query!
State/province [58]
0
0
Santa Catarina
Query!
Country [59]
0
0
Brazil
Query!
State/province [59]
0
0
Sao Paulo
Query!
Country [60]
0
0
Brazil
Query!
State/province [60]
0
0
Fortaleza
Query!
Country [61]
0
0
Bulgaria
Query!
State/province [61]
0
0
Ruse
Query!
Country [62]
0
0
Bulgaria
Query!
State/province [62]
0
0
Plovdiv
Query!
Country [63]
0
0
Bulgaria
Query!
State/province [63]
0
0
Sofia
Query!
Country [64]
0
0
Canada
Query!
State/province [64]
0
0
Alberta
Query!
Country [65]
0
0
Canada
Query!
State/province [65]
0
0
British Columbia
Query!
Country [66]
0
0
Canada
Query!
State/province [66]
0
0
Newfoundland and Labrador
Query!
Country [67]
0
0
Canada
Query!
State/province [67]
0
0
Nova Scotia
Query!
Country [68]
0
0
Canada
Query!
State/province [68]
0
0
Ontario
Query!
Country [69]
0
0
Canada
Query!
State/province [69]
0
0
Quebec
Query!
Country [70]
0
0
Colombia
Query!
State/province [70]
0
0
Antioquia
Query!
Country [71]
0
0
Colombia
Query!
State/province [71]
0
0
Atlantico
Query!
Country [72]
0
0
Colombia
Query!
State/province [72]
0
0
Cundinamarca
Query!
Country [73]
0
0
Colombia
Query!
State/province [73]
0
0
Distrito Capital De Bogotá
Query!
Country [74]
0
0
Colombia
Query!
State/province [74]
0
0
Distrito Capital
Query!
Country [75]
0
0
Colombia
Query!
State/province [75]
0
0
Risaralda
Query!
Country [76]
0
0
Colombia
Query!
State/province [76]
0
0
Valle Del Cauca
Query!
Country [77]
0
0
Denmark
Query!
State/province [77]
0
0
Copenhagen
Query!
Country [78]
0
0
Denmark
Query!
State/province [78]
0
0
København
Query!
Country [79]
0
0
Germany
Query!
State/province [79]
0
0
Baden-Wurttemberg
Query!
Country [80]
0
0
Germany
Query!
State/province [80]
0
0
Saxony
Query!
Country [81]
0
0
Germany
Query!
State/province [81]
0
0
Hamburg
Query!
Country [82]
0
0
Germany
Query!
State/province [82]
0
0
Hannover
Query!
Country [83]
0
0
Hungary
Query!
State/province [83]
0
0
Heves
Query!
Country [84]
0
0
Hungary
Query!
State/province [84]
0
0
Jász-Nagykun-Szolnok
Query!
Country [85]
0
0
Hungary
Query!
State/province [85]
0
0
Zala
Query!
Country [86]
0
0
Hungary
Query!
State/province [86]
0
0
Budapest
Query!
Country [87]
0
0
Hungary
Query!
State/province [87]
0
0
Szeged
Query!
Country [88]
0
0
India
Query!
State/province [88]
0
0
Andhra Pradesh
Query!
Country [89]
0
0
India
Query!
State/province [89]
0
0
Gujarat
Query!
Country [90]
0
0
India
Query!
State/province [90]
0
0
Karnataka
Query!
Country [91]
0
0
India
Query!
State/province [91]
0
0
Maharashtra
Query!
Country [92]
0
0
India
Query!
State/province [92]
0
0
Rajasthan
Query!
Country [93]
0
0
India
Query!
State/province [93]
0
0
Tamil Nadu
Query!
Country [94]
0
0
India
Query!
State/province [94]
0
0
Uttar Pradesh
Query!
Country [95]
0
0
India
Query!
State/province [95]
0
0
Delhi
Query!
Country [96]
0
0
India
Query!
State/province [96]
0
0
Mangalore
Query!
Country [97]
0
0
Israel
Query!
State/province [97]
0
0
Haifa
Query!
Country [98]
0
0
Korea, Republic of
Query!
State/province [98]
0
0
Jeollabuk-Do
Query!
Country [99]
0
0
Korea, Republic of
Query!
State/province [99]
0
0
Nowon-gu
Query!
Country [100]
0
0
Korea, Republic of
Query!
State/province [100]
0
0
Seoul
Query!
Country [101]
0
0
Latvia
Query!
State/province [101]
0
0
Kraslavas Nov.
Query!
Country [102]
0
0
Latvia
Query!
State/province [102]
0
0
Daugavpils
Query!
Country [103]
0
0
Latvia
Query!
State/province [103]
0
0
Riga
Query!
Country [104]
0
0
Malaysia
Query!
State/province [104]
0
0
Kedah
Query!
Country [105]
0
0
Malaysia
Query!
State/province [105]
0
0
Kuala Lumpur
Query!
Country [106]
0
0
Malaysia
Query!
State/province [106]
0
0
Kubang Kerian
Query!
Country [107]
0
0
Malaysia
Query!
State/province [107]
0
0
Taiping
Query!
Country [108]
0
0
Mexico
Query!
State/province [108]
0
0
Distrito Federal
Query!
Country [109]
0
0
Mexico
Query!
State/province [109]
0
0
Jalisco
Query!
Country [110]
0
0
Mexico
Query!
State/province [110]
0
0
Yucatán
Query!
Country [111]
0
0
Mexico
Query!
State/province [111]
0
0
Aguascalientes
Query!
Country [112]
0
0
Mexico
Query!
State/province [112]
0
0
Durango
Query!
Country [113]
0
0
Mexico
Query!
State/province [113]
0
0
Veracruz
Query!
Country [114]
0
0
Philippines
Query!
State/province [114]
0
0
IloIlo
Query!
Country [115]
0
0
Philippines
Query!
State/province [115]
0
0
Metro Manila
Query!
Country [116]
0
0
Philippines
Query!
State/province [116]
0
0
Metropolitan Manila
Query!
Country [117]
0
0
Philippines
Query!
State/province [117]
0
0
NCR
Query!
Country [118]
0
0
Philippines
Query!
State/province [118]
0
0
Cebu City
Query!
Country [119]
0
0
Philippines
Query!
State/province [119]
0
0
Quezon City
Query!
Country [120]
0
0
Poland
Query!
State/province [120]
0
0
Lesser Poland
Query!
Country [121]
0
0
Poland
Query!
State/province [121]
0
0
Malopolska
Query!
Country [122]
0
0
Poland
Query!
State/province [122]
0
0
Chojnice
Query!
Country [123]
0
0
Russian Federation
Query!
State/province [123]
0
0
Leningrad Region
Query!
Country [124]
0
0
Russian Federation
Query!
State/province [124]
0
0
Saratov Region
Query!
Country [125]
0
0
Russian Federation
Query!
State/province [125]
0
0
Novosibirsk
Query!
Country [126]
0
0
Russian Federation
Query!
State/province [126]
0
0
Rostov on Don
Query!
Country [127]
0
0
Singapore
Query!
State/province [127]
0
0
Singapore
Query!
Country [128]
0
0
South Africa
Query!
State/province [128]
0
0
Free State
Query!
Country [129]
0
0
South Africa
Query!
State/province [129]
0
0
Gauteng
Query!
Country [130]
0
0
South Africa
Query!
State/province [130]
0
0
Val De Grace
Query!
Country [131]
0
0
South Africa
Query!
State/province [131]
0
0
Somerset West
Query!
Country [132]
0
0
Spain
Query!
State/province [132]
0
0
Madrid
Query!
Country [133]
0
0
Thailand
Query!
State/province [133]
0
0
Bangkok
Query!
Country [134]
0
0
Thailand
Query!
State/province [134]
0
0
Chiang Mai
Query!
Country [135]
0
0
Ukraine
Query!
State/province [135]
0
0
Dnipropetrovs'ka Oblast'
Query!
Country [136]
0
0
Ukraine
Query!
State/province [136]
0
0
Zaporizhzhia Region
Query!
Country [137]
0
0
Ukraine
Query!
State/province [137]
0
0
Chernivtsi
Query!
Country [138]
0
0
Ukraine
Query!
State/province [138]
0
0
Ivano-Frankivsk
Query!
Country [139]
0
0
Ukraine
Query!
State/province [139]
0
0
Kharkiv
Query!
Country [140]
0
0
Ukraine
Query!
State/province [140]
0
0
Kherson
Query!
Country [141]
0
0
Ukraine
Query!
State/province [141]
0
0
Kyiv
Query!
Country [142]
0
0
Ukraine
Query!
State/province [142]
0
0
Odesa
Query!
Country [143]
0
0
Ukraine
Query!
State/province [143]
0
0
Poltava
Query!
Country [144]
0
0
Ukraine
Query!
State/province [144]
0
0
Vinnytsia
Query!
Country [145]
0
0
Ukraine
Query!
State/province [145]
0
0
Zaporizhzhia
Query!
Country [146]
0
0
United Kingdom
Query!
State/province [146]
0
0
East Midland
Query!
Country [147]
0
0
United Kingdom
Query!
State/province [147]
0
0
Greater Manchester
Query!
Country [148]
0
0
United Kingdom
Query!
State/province [148]
0
0
Lancashire
Query!
Country [149]
0
0
United Kingdom
Query!
State/province [149]
0
0
Merseyside
Query!
Country [150]
0
0
United Kingdom
Query!
State/province [150]
0
0
Staffordshire
Query!
Country [151]
0
0
United Kingdom
Query!
State/province [151]
0
0
West Yorkshire
Query!
Country [152]
0
0
United Kingdom
Query!
State/province [152]
0
0
Barnsley
Query!
Country [153]
0
0
United Kingdom
Query!
State/province [153]
0
0
Blackpool
Query!
Country [154]
0
0
United Kingdom
Query!
State/province [154]
0
0
Chelmsford
Query!
Country [155]
0
0
United Kingdom
Query!
State/province [155]
0
0
Manchester
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
Allergan
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
A 52-week study to compare the efficacy of relamorelin with that of placebo in participants with diabetic gastroparesis (DG) with respect to the core signs and symptoms of diabetic gastroparesis.
Query!
Trial website
https://clinicaltrials.gov/study/NCT03383146
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Harvy Schneier
Query!
Address
0
0
Allergan
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Type
Other Details
Attachment
Study protocol
https://cdn.clinicaltrials.gov/large-docs/46/NCT03383146/Prot_002.pdf
Statistical analysis plan
https://cdn.clinicaltrials.gov/large-docs/46/NCT03383146/SAP_001.pdf
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results are available at
https://clinicaltrials.gov/study/NCT03383146
Download to PDF